Figure 4.
Identification of CD206 as a predictor of outcome in AML. (a and b) OS and EFS analyses based on mRNA expression levels of the four M2 marker genes (CD68, CD163, CD206, and CD204) in CN-AML patients from Cohort 2 (a) and Cohort 3 (b). Patients were stratified in two groups using the median expression value as a cutoff. The p-values were computed using log-rank tests.